Coverage For Off-Label Cancer Drugs, Genomic Tests Tackled In Policy Report
This article was originally published in The Pink Sheet Daily
Executive Summary
The Green Park Collaborative seeks public comments on recommended guidelines for insurance coverage of tumor profiling through next-generation DNA sequencing and off-label treatment of targeted cancer drugs.